March 4, 2011 - Occlutech GmbH received a favorable court ruling in Stockholm, Sweden in the ongoing patent litigation case with AGA Medical-St. Jude Medical.
In the ruling by Stockholm’s Tingsratt , the district court of Stockholm, the court does not see any basis for AGA-St Jude's claim that the Occlutech atrial septal defect (ASD) and patent foramen ovale (PFO) occluders violate any patent brought forward in the litigation. The Stockholm court decision is similar to the first instance ruling in the United Kingdom, which was confirmed by the appeal court in the United Kingdom, the last one received mid-2010. The U.K. ruling is final as the U.K. supreme court did not allow an appeal requested by AGA. The favorable Stockholm ruling is also similar to first instance as well as appeal court decisions in The Hague, in the Netherlands, the last one obtained in the end of 2010.
The rulings in Sweden and The Netherlands are subject to appeal by AGA-St. Jude Medical.
Throughout the litigation, Occlutech's owners and investors have funded work in maintaining and substantially strengthening Occlutech's own patent position. In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus arteriosus (PDA) and ventricular septal defect (VSD) in addition to second generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder, a new generation of stent grafts and cardiac valve intervention technologies are being developed.
For more information: www.occlutech.com
June 20, 2024 
